Synovis Life Technologies (NASDAQ: SYNO) was downgraded by equities research analysts at Feltl & Co. from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
Separately, analysts at Roth Capital downgraded shares of Synovis Life Technologies from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, December 14th.
Synovis Life Technologies, Inc. (Synovis) is a diversified medical device company engaged in developing, manufacturing and marketing mechanical and biological products used by surgical specialties for the repair of soft tissue damaged or destroyed by disease or injury. Synovis’s products include implantable biomaterials for soft tissue repair, devices for microsurgery and surgical tools. On July 17, 2009, the Company, through its wholly owned subsidiary Synovis Orthopedic and Woundcare, Inc. (Ortho & Wound), acquired Pegasus Biologics, Inc.
Shares of Synovis Life Technologies traded up 0.04% during mid-day trading on Wednesday, hitting $27.90. Synovis Life Technologies has a 52 week low of $13.21 and a 52 week high of $27.97. The stock’s 50-day moving average is $23.71 and its 200-day moving average is $18.59. The company has a market cap of $311.6 million and a price-to-earnings ratio of 38.21.